Free tool
Rare disease stocks
We cover 23 companies grouped under the Rare disease theme. The median market value in the group is $3.12B. Across the group, the median move over the past trading day is +1.72%. 81% of the 21 with a 200-day average trade above it. Price change over the past year runs from +5.0% to +273.0% across the middle 80 percent of the group, with a median of +65.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
23 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.16 | +0.37% | +11.49% | +12.68% | Oct 26, 2026 |
| 4151.T | Kyowa Kirin Co., Ltd. | 2,596.00 JPY | −2.26% | +3.26% | +3.09% | Nov 2, 2026 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $113.35 | +6.80% | +7.94% | +14.26% | Nov 3, 2026 |
| ORKA | Oruka Therapeutics, Inc. | $101.82 | +12.88% | +260.17% | +601.72% | Nov 11, 2026 |
| LQDA | Liquidia Corporation | $70.49 | −16.50% | +124.49% | +168.53% | Nov 3, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $80.20 | +26.23% | +90.93% | +142.74% | Oct 27, 2026 |
| TVTX | Travere Therapeutics, Inc. | $67.01 | +18.23% | +69.56% | +288.91% | Oct 29, 2026 |
| MIRM | Mirum Pharmaceuticals, Inc. | $98.08 | −14.12% | +25.63% | +36.58% | Nov 4, 2026 |
| EWTX | Edgewise Therapeutics, Inc. | $44.21 | +6.27% | +86.15% | +209.16% | Nov 5, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.46 | +92.20% | +228.02% | +340.71% | Nov 5, 2026 |
| MANE | Veradermics, Incorporated | $102.35 | −8.14% | +171.13% | +171.13% | Nov 12, 2026 |
| ARQT | Arcutis Biotherapeutics, Inc. | $24.86 | −10.70% | −14.28% | +58.44% | Oct 27, 2026 |
| VRDN | Viridian Therapeutics, Inc. | $24.18 | +22.74% | −21.19% | +30.21% | Nov 5, 2026 |
| PHVS | Pharvaris N.V. | $37.31 | +9.83% | +40.90% | +57.76% | Nov 12, 2026 |
| RARE | Ultragenyx Pharmaceutical Inc. | $26.46 | −1.60% | +12.12% | −9.60% | Nov 3, 2026 |
| VERA | Vera Therapeutics, Inc. | $35.28 | +0.28% | −27.44% | +65.32% | Nov 5, 2026 |
| NKTR | Nektar Therapeutics | $74.96 | +5.06% | +72.64% | +176.20% | Nov 12, 2026 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $9.83 | +2.61% | +31.07% | +17.16% | Nov 2, 2026 |
| MLYS | Mineralys Therapeutics, Inc. | $26.34 | −3.20% | −26.24% | +78.70% | Nov 10, 2026 |
| COAG | Hemab Therapeutics Holdings, Inc. | $49.65 | −1.47% | +46.03% | +46.03% | Nov 16, 2026 |
| ZBIO | Zenas BioPharma, Inc. | $33.77 | +2.89% | −2.12% | +103.93% | Nov 12, 2026 |
| STOK | Stoke Therapeutics, Inc. | $33.46 | +14.16% | +8.28% | +77.32% | Nov 3, 2026 |
| ADMA | ADMA Biologics, Inc. | $9.72 | +14.62% | −45.64% | −42.86% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.